Addex Therapeutics Ltd - ADR Stock

$11.18

1.15% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Addex Therapeutics Ltd - ADR Stock price

$11.18

-278.82 96.14% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.13 1.15%

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$9.16m
Enterprise Value	$7.39m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	4.77
P/S ratio (TTM) P/S ratio	5.91
P/B ratio (TTM) P/B ratio	negative
Revenue growth (TTM) Revenue growth	-13.17%
Revenue (TTM) Revenue	$1.55m
EBIT (operating result TTM) EBIT	$-9.76m
Free Cash Flow (TTM) Free Cash Flow	$-8.73m
Cash position	$1.81m
EPS (TTM) EPS	$-17.95
P/E forward	negative
P/S forward	7.55
EV/Sales forward	6.09
Short interest	0.12%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

1x Buy

33%

2x Sell

67%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Buy

33%

Sell

67%

Analyst Estimates with Stock Price Targets

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '24		+/- %
Revenue	1.55 1.55	13% 13% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.76 4.76	21% 21% 307%
- Research and Development Expense	6.03 6.03	54% 54% 389%
EBITDA	-9.50 -9.50	46% 46% -613%
- Depreciation and Amortization	0.26 0.26	21% 21% 17%
EBIT (Operating Income) EBIT	-9.76 -9.76	45% 45% -630%
Net Profit	-13 -13	30% 30% -819%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Addex Therapeutics Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

4 days ago

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte N...

Positive

Invezz

●

11 days ago

Why Addex Therapeutics stock skyrocketed 70% on Tuesday

Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.

Neutral

GlobeNewsWire

●

12 days ago

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric...

More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office	Switzerland
CEO	Tim Dyer
Employees	23
Founded	2002
Website	www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now